{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:04:42Z","timestamp":1786619082879,"version":"build-2736575974"},"reference-count":59,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Almost 1 billion people worldwide have acne, and oral tetracyclines, including doxycycline and minocycline, are effective and frequently prescribed treatments for acne. However, there is growing concern for the development of antibiotic resistance with such widespread utilization by dermatologists. Additionally, tetracyclines are known to have various potential side effects, including gut dysbiosis, gastrointestinal upset, photosensitivity, dizziness, and vertigo. However, in 2018 a novel narrow-spectrum tetracycline, sarecycline, was Food and Drug Administration-approved to treat moderate-to-severe acne vulgaris in patients 9-years-old and above. Sarecycline was designed to target Cutibacterium acnes, the pathogenic bacterium in acne vulgaris, which may reduce the risk of resistance. This paper examines the growing concerns of antibiotic resistance due to oral tetracycline usage in the treatment of acne vulgaris, with a focus on the promising third-generation, narrow-spectrum tetracycline, sarecycline.<\/jats:p>","DOI":"10.3390\/antibiotics11081032","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T21:49:02Z","timestamp":1659304142000},"page":"1032","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-8266","authenticated-orcid":false,"given":"Madisen","family":"Swallow","sequence":"first","affiliation":[{"name":"Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Fan","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-8308","authenticated-orcid":false,"given":"Christopher","family":"Bunick","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjd.13462","article-title":"A global perspective on the epidemiology of acne","volume":"172","author":"Tan","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_2","first-page":"13","article-title":"The epidemiology of acne vulgaris in late adolescence","volume":"7","author":"Lynn","year":"2016","journal-title":"Adolesc. Health Med. Ther."},{"key":"ref_3","unstructured":"Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629\u2013655."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMcp1702493","article-title":"Acne vulgaris","volume":"379","author":"Zaenglein","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaad.2007.06.045","article-title":"The prevalence of acne in adults 20 years and older","volume":"58","author":"Collier","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","first-page":"2021-8-6","article-title":"Dermatology: How to manage acne vulgaris","volume":"10","author":"Leung","year":"2020","journal-title":"Drugs Context"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/bjd.12912","article-title":"Epidemiology and extracutaneous comorbidities of severe acne in adolescence: A U.S. population-based study","volume":"170","author":"Silverberg","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1046\/j.1365-2133.2001.04346.x","article-title":"Acne prevalence, knowledge about acne and psychological morbidity in mid-adolescence: A community-based study","volume":"145","author":"Smithard","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1365-4632.2009.04002.x","article-title":"Diet and acne: A review of the evidence","volume":"48","author":"Spencer","year":"2009","journal-title":"Int. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/jid.2010.264","article-title":"Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: A population-based study","volume":"131","author":"Halvorsen","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(11)60321-8","article-title":"Acne vulgaris","volume":"379","author":"Williams","year":"2012","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40257-017-0267-z","article-title":"Oral Antibacterial Therapy for Acne Vulgaris: An Evidence-Based Review","volume":"18","author":"Bienenfeld","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40257-020-00560-w","article-title":"Oral Antibiotics for Acne","volume":"22","author":"Patel","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_15","first-page":"581","article-title":"Efficacy and Safety of Subantimicrobial Dose, Modified-Release Doxycycline 40 mg Versus Doxycycline 100 mg Versus Placebo for the treatment of Inflammatory Lesions in Moderate and Severe Acne: A Randomized, Double-Blinded, Controlled Study","volume":"14","author":"Moore","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_16","first-page":"21","article-title":"Safety and efficacy of a new extended-release formulation of minocycline","volume":"78","author":"Fleischer","year":"2006","journal-title":"Cutis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/IDR.S173867","article-title":"Antibiotic resistance: A rundown of a global crisis","volume":"11","author":"Aslam","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/431899a","article-title":"Antibiotics at the crossroads","volume":"431","author":"Nathan","year":"2004","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.chemosphere.2015.12.084","article-title":"A review of the influence of treatment strategies on antibiotic resistant bacteria and antibiotic resistance genes","volume":"150","author":"Sharma","year":"2016","journal-title":"Chemosphere"},{"key":"ref_20","unstructured":"(2022, July 27). World Economic Forum. Global Risks. Available online: https:\/\/reports.weforum.org\/global-risks-2013\/?doing_wp_cron=1659126758.5001749992370605468750."},{"key":"ref_21","unstructured":"Centers for Disease Control and Prevention (2022, July 27). Antibiotic Resistance Threats in the United States, Available online: https:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jamadermatol.2017.1297","article-title":"Antibiotic Resistance in Acne Treatment","volume":"153","author":"Adler","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1473-3099(15)00527-7","article-title":"Systematic review of antibiotic resistance in acne: An increasing topical and oral threat","volume":"16","author":"Walsh","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_24","first-page":"593","article-title":"Antibiotic resistant acne","volume":"17","author":"Leyden","year":"1976","journal-title":"Cutis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/jdv.16686","article-title":"Antibiotic resistance in acne: Changes, consequences and concerns","volume":"35","author":"Karadag","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0092-8674(00)00216-6","article-title":"The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit","volume":"103","author":"Brodersen","year":"2000","journal-title":"Cell"},{"key":"ref_27","first-page":"201","article-title":"Clinical and physiological factors determining diagnosis and choice of treatment of renovascular hypertension","volume":"21","author":"Maxwell","year":"1967","journal-title":"Circ. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/emboj\/20.8.1829","article-title":"Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3","volume":"20","author":"Pioletti","year":"2001","journal-title":"EMBO J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"a025387","DOI":"10.1101\/cshperspect.a025387","article-title":"Tetracycline Antibiotics and Resistance","volume":"6","author":"Grossman","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1468-3083.2011.04351.x","article-title":"Antibiotic-resistant Propionibacterium acnes among acne patients in a regional skin centre in Hong Kong","volume":"27","author":"Luk","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Alkhawaja, E., Hammadi, S., Abdelmalek, M., Mahasneh, N., Alkhawaja, B., and Abdelmalek, S.M. (2020). Antibiotic resistant Cutibacterium acnes among acne patients in Jordan: A cross sectional study. BMC Dermatol., 20.","DOI":"10.1186\/s12895-020-00108-9"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"adv00295","DOI":"10.2340\/00015555-3654","article-title":"Antibiotic Susceptibility of Cutibacterium acnes Strains Isolated from Israeli Acne Patients","volume":"100","author":"Rimon","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2133.1989.tb01399.x","article-title":"Erythromycin resistant propionibacteria in antibiotic treated acne patients: Association with therapeutic failure","volume":"121","author":"Eady","year":"1989","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1099\/mic.0.040618-0","article-title":"Long-term impacts of antibiotic exposure on the human intestinal microbiota","volume":"156","author":"Jernberg","year":"2010","journal-title":"Microbiol. (Read.)"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/archderm.141.9.1132","article-title":"Antibiotic treatment of acne may be associated with upper respiratory tract infections","volume":"141","author":"Margolis","year":"2005","journal-title":"Arch. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archdermatol.2011.355","article-title":"Association of pharyngitis with oral antibiotic use for the treatment of acne: A cross-sectional and prospective cohort study","volume":"148","author":"Margolis","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2217\/fmb-2019-0199","article-title":"Sarecycline: A narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris","volume":"14","author":"Moore","year":"2019","journal-title":"Future Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/ajg.2010.303","article-title":"Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease","volume":"105","author":"Margolis","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_39","first-page":"634","article-title":"Management of Truncal Acne With Oral Sarecycline: Pooled Results from Two Phase-3 Clinical Trials","volume":"20","author":"Gold","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e1665973","DOI":"10.1080\/2162402X.2019.1665973","article-title":"Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: A pooled analysis of 2740 cancer patients","volume":"8","author":"Huang","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"eabc4552","DOI":"10.1126\/science.abc4552","article-title":"The microbiome and human cancer","volume":"371","author":"Zitvogel","year":"2021","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2147\/CCID.S190473","article-title":"Sarecycline: A review of preclinical and clinical evidence","volume":"13","author":"Moore","year":"2020","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.12788\/cutis.0057","article-title":"Fighting Acne for the Fighting Forces","volume":"106","author":"Brahe","year":"2020","journal-title":"Cutis"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Grada, A., Ghannoum, M.A., and Bunick, C.G. (2022). Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060722"},{"key":"ref_46","unstructured":"(2022, April 10). US Food and Drug Administration Approved Prescribing Information. SEYSARA\u00ae (Sarecycline) Tablets for Oral Use (Package Insert), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/209521Orig1s000TOC.cfm."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Bunick, C.G., Keri, J., Tanaka, S.K., Furey, N., Damiani, G., Johnson, J.L., and Grada, A. (2021). Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation. Antibiotics, 10.","DOI":"10.3390\/antibiotics10040439"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ghannoum, M.A., Long, L., Bunick, C.G., Del Rosso, J.Q., Gamal, A., Tyring, S.K., McCormick, T.S., and Grada, A. (2022). Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota. Antibiotics, 11.","DOI":"10.3390\/antibiotics11030324"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e01297-18","DOI":"10.1128\/AAC.01297-18","article-title":"Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris","volume":"63","author":"Zhanel","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.det.2018.07.002","article-title":"New Concepts, Concerns, and Creations in Acne","volume":"37","author":"Marson","year":"2019","journal-title":"Dermatol. Clin."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e15275","DOI":"10.1111\/dth.15275","article-title":"Sarecycline treatment for acne vulgaris: Rationale for weight-based dosing and limited impact of food intake on clinical efficacy","volume":"35","author":"Grada","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_52","first-page":"333","article-title":"Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study","volume":"17","author":"Leyden","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"20530","DOI":"10.1073\/pnas.2008671117","article-title":"Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome","volume":"117","author":"Batool","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1073\/pnas.1501775112","article-title":"Cryo-EM structure of the tetracycline resistance protein TetM in complex with a translating ribosome at 3.9-A resolution","volume":"112","author":"Arenz","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1073\/pnas.1216691110","article-title":"Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis","volume":"110","author":"Jenner","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","first-page":"3","article-title":"Cutibacterium acnes (formerly Proprionibacterium acnes) and Shoulder Surgery","volume":"78","author":"Elston","year":"2019","journal-title":"Hawaii J. Health Soc. Welf."},{"key":"ref_57","unstructured":"Silverman, E. (2022, July 27). McDonald\u2019s Accused of Dragging Its Feet on Goal of Reducing Antibiotic Use in Beef Supplies. STAT News. Available online: https:\/\/www.statnews.com\/pharmalot\/2021\/11\/29\/mcdonalds-antibiotics-superbugs-livestock-beef\/."},{"key":"ref_58","unstructured":"WHO Antibacterial Pipeline Team (2022, July 27). Lack of Innovation Set to Undermine Antibiotic Performance and Health Gains, Available online: https:\/\/www.who.int\/news\/item\/22-06-2022-22-06-2022-lack-of-innovation-set-to-undermine-antibiotic-performance-and-health-gains."},{"key":"ref_59","unstructured":"(2022, July 27). The AMR Innovation Challenge. The AMR Action Fund. Available online: https:\/\/www.amractionfund.com\/amr-innovation-challenge#page-section-3."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/8\/1032\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:02Z","timestamp":1760140802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/8\/1032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["antibiotics11081032"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11081032","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]}}}